期刊论文

Jian, J.

中文

中华内科杂志

0578-1426

1999

38

8

517-519

10.3760/j.issn:0578-1426.1999.08.004

本校为第一机构

目的　研究血脂康对高脂血症患者血脂的调脂作用及对血栓素A2 （TXA2 ）、前列环素（PGI2 ）的影响。方法　 91例原发性高脂血症患者随机分为血脂康组和吉非罗齐对照组 ,分别口服血脂康 1.2g/d或吉非罗齐 1.2g/d ,连服 8周 ,治疗前后测定血脂谱、TXB2 、6 酮 前列腺素F1α（ 6 Keto PGF1α）。结果　 （ 1）服血脂康和吉非罗齐 8周后 ,血清总胆固醇 （TC）分别降低 2 1.6%和 2 0 .4 % ,甘油三酯 （TG）分别降低 2 3 .3 %和 4 0 .3 % ,低密度脂蛋白胆固醇 （LDL C）分别降低 3 3 .3 %和 2 4 .8% ,高密度脂蛋白胆固醇 （HDL C）分别升高 3 3 .7%和 2 6.9% （以上P均

OBJECTIVE: To study the effects of Xuezhikang on lipid profile, thromboxane (TX) A(2), prostacyclin (PGI(2)) in patients with hyperlipidemia. METHODS: 91 patients with hyperlipidemia were randomly divided into a treatment group (n = 47, Xuezhikang 1.2 g/d Bid, p.o) and control group (n = 44, gemfibrozil 1.2 g/d Bid, p.o). serum lipids, TXB(2) and 6-Keto-PGF(1alpha) were determined before and 8 weeks after the treatment. RESULTS: (1) After 8 weeks of treatment, the level of serum total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) decreased by 21.6% (P < 0.01) and 33.3% (P < ...